HR Benecast
Episode 60 - Stop Loss Insurance: What Employers Should Know
Why It Matters
Understanding stop‑loss dynamics is crucial for employers who self‑fund health benefits, as it helps them budget for unpredictable, high‑cost claims and make informed decisions about deductible levels and coverage options. The episode’s insights into rising premium pressures, emerging high‑cost therapies, and market trends equip benefits professionals with the knowledge needed to mitigate financial risk in a volatile healthcare environment.
Key Takeaways
- •2026 stop‑loss premiums rose 12‑15% due to medical inflation.
- •High‑cost claims now include CAR‑T, gene, and biosimilar therapies.
- •Employers increasingly adopt stop‑loss with million‑dollar deductibles.
- •Indexing deductibles to medical trend mitigates premium spikes.
- •Aegis Risk survey provides benchmark data for premium negotiations.
Pulse Analysis
The 2026 stop‑loss renewal cycle marked a sharp shift from a previously soft market to a tighter pricing environment. Medical inflation of 5‑7% translated into 12‑15% premium hikes for many self‑funded plans, especially where deductible levels remained static. This surge reflects carriers catching up after under‑pricing in 2024 and underscores the importance of real‑time market intelligence. Aegis Risk’s annual premium survey, now in its 20th year, aggregates over a billion dollars of data, giving plan sponsors a rare glimpse into negotiated rates and emerging trends.
Large, catastrophic claims are reshaping risk calculations. Inpatient stays complicated by sepsis or multiple comorbidities routinely exceed the million‑dollar threshold, while oncology treatments—particularly CAR‑T and emerging gene‑therapy options—are driving claim sizes into the multi‑million range. Congenital anomalies and high‑cost hemophilia therapies add further volatility. Reinsurers are closely monitoring these categories, though they remain less concerned about regulatory shifts such as prior‑authorization reforms, which have yet to crystallize into binding legislation. The rise of biosimilars, like lower‑cost alternatives to Humira, offers a potential offset, but stop‑loss carriers view them as ancillary to their core catastrophic exposure.
For employers, proactive risk management is essential. Increasing participation in stop‑loss coverage, even at million‑dollar deductibles, provides a budgeting hedge against unpredictable spikes. Adjusting attachment points to mirror medical trend rates—indexing deductibles by 5‑7%—can blunt premium growth without sacrificing protection. Leveraging the Aegis Risk survey equips benefits teams with benchmark data to negotiate more effectively. Finally, a deep dive into existing policies, claim histories, and potential high‑cost claim scenarios positions sponsors to enter renewal discussions with confidence, turning stop‑loss from a reactive safety net into a strategic financial tool.
Episode Description
Ryan Siemers, founder of Aegis Risk, returns to HR Benecast to discuss the latest trends in medical stop loss insurance and what they mean for employers navigating today's self-funded health plan landscape. In this episode, Ryan breaks down current stop loss market cycles, the high-cost claim drivers impacting employer health plans and the legislative and regulatory developments influencing stop loss coverage.
Access Aegis Risk's Medical Stop Loss Premium Survey at Stop Loss Premium Survey | Aegis Risk.
Watch or listen to Benefits Bites and Health Care Headlines.
Register for upcoming Employers Health webinars or watch on demand at Events - Employers Health.
Sign up for our monthly newsletter here.
Find additional helpful benefits strategies and resources at Articles | Employers Health.
Comments
Want to join the conversation?
Loading comments...